Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 28, 2023.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
A duo of experts provide insight on various topics related to the advances in treatment options, diagnosis of the disorder, role of genetics, and potential future research and gene therapies.
In episode 11 of the "How Similar are Biosimilars? A look into the Future with Biosimilars in Multiple Sclerosis" Peer Exchange series, Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.
In the latest edition of our in-depth Q&A series, the director at the Foundation for the National Institutes of Health provided perspective on the effective ways to utilize currently available biomarkers for Alzheimer disease research.
Krzysztof Selmaj, MD, PhD, presents the key results on the safety of other sphinogine-1-phospate (S1P) receptor modulators, such as fingolimod and ponesimod, in the treatment of multiple sclerosis (MS).
The researcher in the department of neurochemistry at the University of Gothenburg in Sweden discussed bloodspot cards as a promising method for collecting blood samples in Alzheimer disease research. [WATCH TIME: 4 minutes]